Skin Care Product Recall: Risk of Bacterial Contamination

The FDA is warning consumers not to use any Clarcon skin products, including Citrushield, Dermassentials, Skin Shield and Total Skin Care, as they may be contaminated with bacteria that could cause serious skin infections.

The skin care product recall involves over-the-counter topical antimicrobial skin sanitizers and hand protectant products made by Clarcon Biological Chemistry Laboratory, Inc., which have been found to contain “high levels of disease-causing bacteria,” according to the FDA. This could cause infections of the skin or underlying tissue, potentially requiring surgery or resulting in permanent damage.

The Clarcon skin care product problems were discovered by the FDA when several samples from the manufacturing plant were analyzed during an inspection that revealed serious deviations from the FDA’s current Good Manufacturing Practice requirements.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

“Findings from the FDA’s recent inspection of the Clarcon facility are particularly concerning because the products are promoted as antimicrobial agents that claim to treat open wounds, damaged skin, and protect againt various infectious diseases,” said that FDA in a statement issued June 8, 2009.

All products manufactured by Clarcon are involved in the recall, including:

  • Citrushield Lotion
  • Dermassentials DermaBarrier
  • Dermassentials by Clarcon Antimicrobial Hand Sanitizer
  • Iron Fist Barrier Hand Treatment
  • Skin Shield Restaurant
  • Skin Shield Industrial
  • Skin Shield Beauty Salon Lotion
  • Total Skin Care Beauty
  • Total Skin Care Work

The recalled skin products were designed primarily for industrial use. Citrushield is a skin protection product marketed toward industrial users who handle harsh chemicals, such as mechanics and janitors. Skin Shield products are usually sold on janitor and restaurant supply websites.

Clarcon Biological Chemistry Laboratory, Inc., based in Roy, Utah, is a relatively new company, with the Citrushield and Dermassentials products released this year. Dermassentials was being sold under the BioGoods Company label.

The FDA has recommended that consumers discard any Clarcon skin products and report any adverse reactions to the FDA’s MedWatch Adverse Event Reporting program. However, product liability lawyers recommend that if any serious skin reactions were caused by the Clarcon skin sanitizers or hand protectants, any remaining product should be preserved in a manner designed to avoid future use until appropriate testing can be completed.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria
Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria (Posted today)

Hundreds of currently pending Bard PowerPort lawsuits over infections, fractures and migration injuries were consolidated into a multidistrict litigation (MDL), but now even more claims present similar allegations that the implantable port catheter system has dangerous design defects that were not adequately disclosed by the manufacturer.

Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters
Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters (Posted today)

A recent report suggests that Johnson & Johnson is offering an additional $1.1 billion to settle talcum powder lawsuits, as part of a proposed $9 billion deal that would resolve all ovarian cancer claims as part of a third bankruptcy filing by the manufacturer.

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 3 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.